Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.37 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | HRH1 | P35367 | 3/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27982463 | 0.83 | TSHR (0.41) | TSHRLMNATAAR1HTR2AHRH1 | |
| SCHEMBL1950756 | 0.78 | TSHR (0.41) | TSHRLMNATAAR1HTR2AHRH1 | |
| SCHEMBL8974394 | 0.76 | LMNA (0.44) | LMNATAAR1HTR2AHRH1TRPA1 | |
| SCHEMBL27825559 | 0.73 | TSHR (0.50) | TSHRLMNATAAR1HTR2AHRH1 | |
| SCHEMBL5304483 | 0.73 | DPP4 (0.44) | LMNATAAR1HTR2A | |
| SCHEMBL3534814 | 0.73 | LMNA (0.46) | LMNATAAR1HTR2AHRH1TRPA1 | |
| SCHEMBL27310163 | 0.73 | LMNA (0.52) | TSHRLMNATRPA1 | |
| SCHEMBL16924897 | 0.70 | TSHR (0.52) | TSHRLMNATAAR1HTR2AHRH1 | |
| SCHEMBL6568105 | 0.70 | TSHR (0.46) | TSHRLMNATAAR1HTR2AHRH1 | |
| SCHEMBL27814103 | 0.70 | SIGMAR1 (0.44) | TSHRLMNAHTR2AHRH1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071984-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-11 | — | — | US | claimed |
| US-9676770-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071984-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | TSHR 3927/4885LMNA 3246/4885TAAR1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.